← Back to Clinical Trials
Recruiting NCT05711056

NCT05711056 Rural Expanded Access to OUD Care & Linkage Using Toxicologists for Telehealth Initiated Treatment

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05711056
Status Recruiting
Phase
Sponsor Emory University
Condition Opioid Use
Study Type INTERVENTIONAL
Enrollment 480 participants
Start Date 2023-08-30
Primary Completion 2026-08

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Sociobehavioral Intervention

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 480 participants in total. It began in 2023-08-30 with a primary completion date of 2026-08.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The overarching goal of this project is to increase the availability of OUD treatment in rural counties in the state of Georgia by using Emergency Department (ED)-based telehealth strategies to initiate MOUD and connect patients to treatment. The investigators will implement a novel collaboration between rural EDs, medical toxicologists at the Georgia Poison Center (GPC), peer recovery coaches (PRCs) and RCOs throughout Georgia to bridge the gap between OUD treatment need in rural EDs and specialty physician availability at the GPC. Research activities will be conducted during two broad phases, at three rural EDs in Georgia: planning and implementation. During the planning phase, aggregate data will be obtained to determine each ED's existing practices treating patients with OUD and opioid withdrawal. During the implementation phase, the researchers will prospectively study a poison center OUD consultation and PRC intervention as it is rolled out at each site, collecting participant-level data. Sites will be rolled into the implementation phase in a stepped-wedge fashion, so there will be times when some sites are in the planning phase while others are in the implementation phase.

Eligibility Criteria

Inclusion Criteria: * Age 18 years or older * English speaking * Clinically sober * Medically and psychiatrically stable Exclusion criteria: * Already receiving MAT or psychotherapy for OUD prior to ED arrival * Prior participation in the study * Unable to provide informed consent * If their clinical condition worsens such that continued participation would be considered unsafe in the opinion of the PRC or ED staff * Prisoners * Individuals who are not yet adults (infants, children, teenagers) * Cognitively impaired or Individuals with Impaired Decision-Making Capacity * Individuals who are not able to clearly understand English

Contact & Investigator

Central Contact

Emily Kiernan, DO

✉ emily.anne.kiernan@emory.edu

📞 412-519-4944

Principal Investigator

Emily Kiernan, DO

PRINCIPAL INVESTIGATOR

Emory University

Frequently Asked Questions

Who can join the NCT05711056 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Opioid Use. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05711056 currently recruiting?

Yes, NCT05711056 is actively recruiting participants. Contact the research team at emily.anne.kiernan@emory.edu for enrollment information.

Where is the NCT05711056 trial being conducted?

This trial is being conducted at Atlanta, United States.

Who is sponsoring the NCT05711056 clinical trial?

NCT05711056 is sponsored by Emory University. The principal investigator is Emily Kiernan, DO at Emory University. The trial plans to enroll 480 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology